- Home
- ATNF vs GLTO Comparison
ATNF vs GLTO Comparison
Compare ATNF & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATNF
- GLTO
- Stock Information
- Founded
- ATNF 2016
- GLTO 2011
- Country
- ATNF United States
- GLTO Denmark
- Employees
- ATNF N/A
- GLTO N/A
- Industry
- ATNF Biotechnology: Pharmaceutical Preparations
- GLTO Biotechnology: Pharmaceutical Preparations
- Sector
- ATNF Health Care
- GLTO Health Care
- Exchange
- ATNF Nasdaq
- GLTO Nasdaq
- Market Cap
- ATNF 3.8M
- GLTO 4.0M
- IPO Year
- ATNF N/A
- GLTO 2020
- Fundamental
- Price
- ATNF $1.05
- GLTO $3.29
- Analyst Decision
- ATNF
- GLTO Buy
- Analyst Count
- ATNF 0
- GLTO 1
- Target Price
- ATNF N/A
- GLTO $10.00
- AVG Volume (30 Days)
- ATNF 43.3K
- GLTO 86.7K
- Earning Date
- ATNF 05-15-2025
- GLTO 05-08-2025
- Dividend Yield
- ATNF N/A
- GLTO N/A
- EPS Growth
- ATNF N/A
- GLTO N/A
- EPS
- ATNF N/A
- GLTO N/A
- Revenue
- ATNF N/A
- GLTO N/A
- Revenue This Year
- ATNF N/A
- GLTO N/A
- Revenue Next Year
- ATNF N/A
- GLTO N/A
- P/E Ratio
- ATNF N/A
- GLTO N/A
- Revenue Growth
- ATNF N/A
- GLTO N/A
- 52 Week Low
- ATNF $0.66
- GLTO $2.01
- 52 Week High
- ATNF $17.75
- GLTO $16.07
- Technical
- Relative Strength Index (RSI)
- ATNF 49.77
- GLTO 59.33
- Support Level
- ATNF $1.01
- GLTO $3.05
- Resistance Level
- ATNF $1.10
- GLTO $3.49
- Average True Range (ATR)
- ATNF 0.08
- GLTO 0.26
- MACD
- ATNF -0.01
- GLTO 0.04
- Stochastic Oscillator
- ATNF 35.29
- GLTO 75.76
About ATNF 180 Life Sciences Corp.
180 Life Sciences Corp was formed as a clinical-stage biotechnology company, focused on the development of therapeutics for unmet medical needs in chronic pain, inflammation, and fibrosis by employing research, and, where appropriate, combination therapy. In addition, it has acquired certain source code and intellectual property relating to the back-end technology platform to operate an online blockchain casino, and moving forward, it plans to focus the majority of its operations on the creation of the online blockchain casino, while looking to monetize certain prior development-stage therapeutic product candidates for unmet medical needs. It has one reportable operating segment, iGaming.
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.